Reston, VA – January 23, 2014 – Cooley LLP announced today that it advised GlycoMimetics, Inc. on its initial public offering. The offering was the first US IPO of 2014. GlycoMimetics is a Maryland-based clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company now trades on the NASDAQ Global Stock Market under the symbol, "GLYC."
The Cooley corporate and securities team advising GlycoMimetics included partners Brent Siler, Christian Plaza and Darren DeStefano along with special counsel Brian Leaf and associates Katie Kazem and Mark Ballantyne. Critical support for the offering was provided by partners Natasha Leskovsek and Drew Gantt and associate David Sclar (regulatory); partner Mike Tuscan and associate Sandhya Deo (intellectual property); partner Ken Krisko and associate Noelle Dubiansky (life sciences); partner Thomas Welk and associates Keith Ranta and Justin Ho (compensation & benefits); and partners Susan Philpot and Mark Windfeld-Hansen (tax).
This offering follows on Cooley's record year in the capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.